Left atrial appendage closure for stroke prevention in atrial fibrillation: Final report from the French left atrial appendage closure registry. Issue 4 (29th May 2021)

• Record Type: Journal Article
• Authors: Teiger, Emmanuel; Thambo, Jean‐Benoit; Defaye, Pascal; Hermida, Jean‐Sylvain; Abbey, Sélim; Klug, Didier; Juliard, Jean‐Michel; Spaulding, Christian; Armero, Sébastien; Champagnac, Didier; Bhugaloo, Hamza; Ternacle, Julien; Lellouche, Nicolas; Audureau, Etienne; Le Corvoisier, Philippe
• Is Part Of: Catheterization and cardiovascular interventions. Volume 98:Issue 4(2021)
• Page Start: 788
• Page End: 799
• Publication Date: 2021-05-29
• Subjects: anticoagulant -- atrial fibrillation -- left atrial appendage closure -- stroke; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.29795
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Objectives: The French left atrial appendage (LAA) closure registry (FLAAC) aimed to assess the safety and efficacy of LAA closure in daily practice. Background: LAA closure has emerged as an alternative for preventing thromboembolic events (TE) in patients with non‐valvular atrial fibrillation (NVAF). Clinical data in this field remains limited and few investigator‐initiated, real‐world registries have been reported. Methods: This nationwide, prospective study was performed in 36 French centers. The primary endpoint was the TE rate after successful LAA closure. Results: The FLAAC registry included 816 patients with a mean age of 75.5 ± 0.3 years, mean follow‐up of 16.0 ± 0.3 months, high TE (CHA2 DS2 ‐VASc score: 4.6 ± 0.1) and bleeding risks (HAS‐BLED score: 3.2 ± 0.05) and common contraindications to long‐term anticoagulation (95.7%). Procedure or device‐related serious adverse events occurred in 49 (6.0%) patients. The annual rate of ischemic stroke/systemic embolism was 3.3% (2.4–4.6). This suggests a relative 57% reduction compared to the risk of stroke in historical NVAF populations without antithrombotic therapy. By multivariate analysis, history of TE was the only factor associated with stroke/systemic embolism during follow‐up (HR, 3.3 [1.58–6.89], p = 0.001). The annual mortality rate was 10.2% (8.4–12.3). Most of the deaths were due to comorbidities or underlying cardiovascular diseases and unrelated to the device or to TE. Conclusions: Our study suggests that LAA closure can be an option in patients with NVAF. Long‐term follow‐up mortality was high, mostly due to comorbidities and underlying cardiovascular diseases, highlighting the importance of multidisciplinary management after LAA closure. Registration: NCT02252861.